Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Y-mAbs Therapeutics (NASDAQ:YMAB) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 0 | 1 | 1 | 0 |
| Last 30D | 1 | 0 | 1 | 1 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $14.75, a high estimate of $22.00, and a low estimate of $7.00. Experiencing a 13.24% decline, the current average is now lower than the previous average price target of $17.00.
Interpreting Analyst Ratings: A Closer Look
The standing of Y-mAbs Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Key Insights:
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Y-mAbs Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Y-mAbs Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Y-mAbs Therapeutics's Background
A Deep Dive into Y-mAbs Therapeutics's Financials
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Net Margin: Y-mAbs Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -37.91% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Y-mAbs Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.45% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Y-mAbs Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.28% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Y-mAbs Therapeutics's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
